1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
14
Active Trials
200 recruiting
7
Rare Diseases
across 17 areas
0
News (30d)
Quiet
Jiangsu Hengrui Medicine Co., Ltd is a company with 1 orphan drug designation across 7 rare diseases. Active clinical trials in 14 indications. 7 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Parkinson disease | - | Des.TrialAppr. |
| breast cancer | - | Des.TrialAppr. |
| cancer | - | Des.TrialAppr. |
| cystic fibrosis | - | Des.TrialAppr. |
| diabetes mellitus | - | Des.TrialAppr. |
| hepatocellular carcinoma | camrelizumab | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
| vitiligo | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
98
overlap in 2+ diseases
0/9
candidate diseases
0
avg importance: 0
7
affecting portfolio
0% of portfolio targets high unmet need diseases
98
overlap in 2+ diseases
0/9
candidate diseases
0
avg importance: 0
7
affecting portfolio